Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of programmed cell death-ligand 1 (PD-L1) compared to other breast cancers, providing the rationale for the recently app...

Full description

Bibliographic Details
Main Authors: Simona Camorani, Margherita Passariello, Lisa Agnello, Silvia Esposito, Francesca Collina, Monica Cantile, Maurizio Di Bonito, Ilya V. Ulasov, Monica Fedele, Antonella Zannetti, Claudia De Lorenzo, Laura Cerchia
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Aptamer
Antitumor immunity
PDGFRβ
PD-L1 monoclonal antibody
TNBC
Tumor microenvironment
Online Access:http://link.springer.com/article/10.1186/s13046-020-01694-9

Internet

http://link.springer.com/article/10.1186/s13046-020-01694-9

Similar Items